- The efficacy and safety of taletrectinib in patients with TKI-naive or crizotinib-pretreated ROS1-positive non-small cell lung cancer (NSCLC).Li, Wei; Yang, Nong; Ma, HuiWen; Fan, Huijie; Li, Kunyan; Wu, Huijuan; Yu, Qitao; Wang, Yongsheng; Meng, Xue; Wang, Xicheng; Qin, Xintian; Wang, Ziping; Liu, Yunpeng; Tao, Min; Zhuang, Wu; Fang, Yong; Sun, Ping; Lu, Kaihua; Wu, Jingxun; Zhou, CaicunAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 1
- The efficacy and safety of TQ-B3101 monotherapy in the first-line treatment in patients with ROS1-positive non-small cell lung cancerLu, S.; Pan, H.; Wu, L.; Yao, Y.; He, J.; Wang, Y.; Wang, X.; Wang, X.; Cai, X.; Yu, Y.; Ma, Z.; Min, X.; Yang, Z.; Cao, L.; Yang, H.; Shu, Y.; Zhuang, W.; Cang, S.; Fang, J.; Li, K.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 2
- SAF-189s in previously treated patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC): Results from the dose-finding portion in a single-arm, first-in-human phase I/II study.Yang, Jin-Ji; Zhou, Jianying; Yang, Nong; Wu, Zhuli; Sun, Juan; Hui, Ai-Min; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2020-05-29 To 2020-05-31.被引 3
会议论文
A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer
17阅读
